Two anti-CD38 antibodies engineered for linkage to anti-tumor toxins are TAK-169, which has shown promising results in preclinical research [88], and MT-0169, for which a Phase I dose-escalation study (NCT04017130) suggested possible utility in extramedullary MM. This evidence concerns the gene CD38 and Miyoshi myopathy.